Adtalem Global Education Inc ATGE

$98.54 +1.90 (1.97%)

Valuation

Market cap
3,400,516,000
Revenue TTM
$1,788,290,000
Net income TTM
$237,070,000
PE ratio
12.45
Forward PE
12.49
Profit margin
13.26%
Debt to equity
0.37

Trading

Volume
683,100
Avg volume
465,246
Day's range
$95.90 – $99.72
Shares out
34,509,000
Stochastic %K
58%
Beta
0.71
Analysts
Strong Sell
Price target
$161.50

Price

Company profile

Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary. The company offers degree and non-degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecond...

Show more

Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary. The company offers degree and non-degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice. It also operates Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The company was formerly known as Adtalem Global Education Inc. and changed its name to Covista Inc. in February 2026. Covista Inc. was incorporated in 1987 and is headquartered in Chicago, Illinois.

Industry
Education & Training Services
Sector
Consumer Defensive
Phone
312 651 1400
Website
https://www.covista.com
Address
233 South Wacker Drive, Suite 800, Chicago, United States

Latest news

No headlines yet.